Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis
Authors
Keywords
-
Journal
BMC Medicine
Volume 18, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-04-20
DOI
10.1186/s12916-020-01549-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Evaluation of the impact of thyroiditis development in patients receiving immunotherapy with programmed cell death-1 inhibitors
- (2019) Matthew Lei et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab
- (2019) Hiroki Ishihara et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors
- (2019) Wouter Ouwerkerk et al. MELANOMA RESEARCH
- Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice
- (2019) Beung-Chul Ahn et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Immune-related adverse events predict the therapeutic efficacy of anti–PD-1 antibodies in cancer patients
- (2019) J. Rogado et al. EUROPEAN JOURNAL OF CANCER
- Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients
- (2019) Alessio Cortellini et al. Clinical Lung Cancer
- Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study
- (2019) Birgitte Bjørnhart et al. ACTA ONCOLOGICA
- Association of Checkpoint Inhibitor–Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non–Small Cell Lung Cancer
- (2019) Fiamma Berner et al. JAMA Oncology
- Clinical significance of signs of autoimmune colitis in 18F-fluorodeoxyglucose positron emission tomography-computed tomography of 100 stage-IV melanoma patients
- (2019) Nina Lang et al. Immunotherapy
- High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma
- (2018) Alexander T. Faje et al. CANCER
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study
- (2018) Daichi Fujimoto et al. LUNG CANCER
- Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab
- (2018) Koichi Sato et al. LUNG CANCER
- Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center
- (2018) Aaron Lisberg et al. Cancer Immunology Research
- Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer
- (2018) Koji Haratani et al. JAMA Oncology
- Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non–Small-cell Lung Cancer
- (2018) Dwight H. Owen et al. Clinical Lung Cancer
- Efficacy of Nivolumab and Pembrolizumab in Patients with Advanced Nonsmall Cell Lung Cancer Needing Treatment Interruption Due to Adverse Events: A Retrospective Multi-Center Analysis
- (2018) Doran Ksienski et al. Clinical Lung Cancer
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
- (2018) Daniel Y. Wang et al. JAMA Oncology
- Can benign lymphoid tissue changes in 18F-FDG PET/CT predict response to immunotherapy in metastatic melanoma?
- (2018) Christos Sachpekidis et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
- (2018) Miguel F. Sanmamed et al. CELL
- Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non–small-cell Lung Cancer
- (2018) Mathieu Grangeon et al. Clinical Lung Cancer
- Association Between Immune-Related Adverse Events and Clinical Efficacy in Patients with Melanoma Treated With Nivolumab: A Multicenter Retrospective Study
- (2018) Naoto Okada et al. CLINICAL THERAPEUTICS
- Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis
- (2018) Biagio Ricciuti et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma
- (2018) Alice Indini et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis
- (2018) Cheng Xu et al. BMJ-British Medical Journal
- Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors
- (2018) Emma C. de Moel et al. Cancer Immunology Research
- Safety of combined PD-1 pathway inhibition and radiation therapy for non-small-cell lung cancer: A multicentric retrospective study from the GFPC
- (2018) Paul Lesueur et al. Cancer Medicine
- Profiling Preexisting Antibodies in Patients Treated With Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer
- (2018) Yukihiro Toi et al. JAMA Oncology
- Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis
- (2017) Sébastien Le Burel et al. EUROPEAN JOURNAL OF CANCER
- The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy
- (2017) Annie N. M. Wong et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma
- (2017) Mario Sznol et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
- (2017) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune‐Related Adverse Events as a Biomarker in Non‐Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors
- (2017) Julia Judd et al. ONCOLOGIST
- The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors
- (2017) Heinz Läubli et al. OncoImmunology
- Antibody-Mediated Thyroid Dysfunction During T-cell Checkpoint Blockade in Patients with Non-Small Cell Lung Cancer
- (2016) J.C. Osorio et al. ANNALS OF ONCOLOGY
- Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study
- (2016) Yasuhiro Nakamura et al. JOURNAL OF DERMATOLOGY
- Anti-programmed cell death protein-1/ligand-1 therapy in different cancers
- (2015) B Homet Moreno et al. BRITISH JOURNAL OF CANCER
- Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes
- (2015) M. Freeman-Keller et al. CLINICAL CANCER RESEARCH
- Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis
- (2015) Hansje-Eva Teulings et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
- (2015) Troy Z. Horvat et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression
- (2015) Martina Sanlorenzo et al. JAMA Dermatology
- Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme
- (2013) Anna Maria Di Giacomo et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- PD-1 is a novel regulator of human B-cell activation
- (2012) Marie-Laure Thibult et al. INTERNATIONAL IMMUNOLOGY
- Enhancing SIV-specific immunity in vivo by PD-1 blockade
- (2008) Vijayakumar Velu et al. NATURE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now